Medigene AG Logo

Medigene AG

MDG1 | F

Overview

Corporate Details

ISIN(s):
DE000A40ESG2
LEI:
391200I33JD2DKZGDX06
Country:
Germany
Address:
Lochhamer Straße 11, 82152 Planegg
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Medigene AG is an immuno-oncology platform company developing T cell receptor (TCR)-guided therapies to treat cancer. Its proprietary End-to-End Platform generates what it terms 3S (sensitive, specific, and safe) T cell receptors for use in multiple therapeutic modalities, including TCR-engineered T cell (TCR-T) therapies, TCR-natural killer cell therapies, and TCR-guided T cell engagers. These technologies are applied to its in-house product pipeline, such as its lead candidate MDG1015, and through partnerships. In August 2025, it was announced that insolvency proceedings were opened for the company's assets.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Medigene AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-04-22 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
German 6.4 KB
2025-04-22 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
German 6.4 KB
2024-10-16 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 2.2 KB
2024-09-18 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 2.2 KB
2024-08-14 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2024 bis zum 30.0…
German 183.1 KB
2024-06-28 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.4 KB
2024-06-28 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.4 KB
2024-05-06 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 789.0 KB
2024-03-28 00:00
Annual Report
English 9.9 MB
2024-03-04 00:00
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2023 bis zum 31.12.2023
German 6.4 KB
2024-03-04 00:00
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2023 bis zum 31.12.2023
German 6.4 KB
2024-02-23 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 2.1 KB
2023-08-17 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2023 bis zum 30.0…
German 171.2 KB
2023-04-26 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 665.8 KB
2022-12-22 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
German 6.4 KB

Automate Your Workflow. Get a real-time feed of all Medigene AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Medigene AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Spago Nanomedical AB Logo
Develops nanomedicine for precision MRI tumor diagnostics and targeted cancer radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Developing first-in-class macrocyclic drugs for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops and out-licenses preclinical cancer drug programs using fragment-based discovery.
Sweden SPRINT
Stayble Therapeutics AB Logo
Develops an injectable therapy for disc-related spinal disorders as an alternative to surgery.
Sweden STABL
Stem Cells Spin Spolka Akcyjna Logo
Commercializes patented MIC-1 stem cell technology for regenerative medicine.
Poland SCS
STRIX GROUP PLC Logo Isle of Man KETL
SynAct Pharma Logo
Developing oral resolution therapies for inflammatory diseases like rheumatoid arthritis.
Sweden SYNACT
SYNAIRGEN PLC Logo
Develops an inhaled interferon beta therapy for severe viral lung infections.
United Kingdom SNG
Terranet B Logo
Develops ultra-fast ADAS anti-collision technology for automakers to protect vulnerable road users.
Sweden TERRNT
Israel TMIS